CD19 and hematologic disorder: As of August 2022, 20 clinical trials are investigating EGFRt-based switchable CAR-T cells in multiple hematological malignancies: 14 in CD19-positive leukemias and lymphomas, 1 in CD22 positive malignancies, 1 in CD19- and CD22-positive leukemias, 2 in CD123-positive acute myeloid leukemia (AML) and 4 in MM.